GVHD,ACUTE
Clinical trials for GVHD,ACUTE explained in plain language.
Never miss a new study
Get alerted when new GVHD,ACUTE trials appear
Sign up with your email to follow new studies for GVHD,ACUTE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for stem cell transplant patients: drug combo targets deadly GVHD
Disease control Recruiting nowThis study tests whether adding the drug ruxolitinib to standard steroids works better than steroids alone for severe graft-versus-host disease (GVHD) after a stem cell transplant. About 54 adults who recently developed severe GVHD will take part. The goal is to see if the combo …
Matched conditions: GVHD,ACUTE
Phase: PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated May 26, 2026 05:22 UTC
-
New hope for stem cell transplant patients: combo therapy targets GVHD
Disease control Recruiting nowThis study tests whether adding the drug ruxolitinib to standard steroids works better than steroids alone for treating grade II acute graft-versus-host disease (GVHD), a common complication after stem cell transplants. About 168 adults who have had a stem cell transplant for blo…
Matched conditions: GVHD,ACUTE
Phase: PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated May 26, 2026 05:21 UTC
-
New drug cocktail aims to stop deadly transplant complication
Disease control Recruiting nowThis study tests whether a new way of giving three drugs (ATG, tacrolimus, and methotrexate) can prevent a serious side effect called graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. The trial will enroll 29 adults aged 18-60 who have a matched don…
Matched conditions: GVHD,ACUTE
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
Blood markers may predict deadly transplant complication early
Knowledge-focused Recruiting nowThis study looks at whether two blood markers, CXCL9 and EASIX, can predict severe acute graft-versus-host disease (GVHD) in people receiving a stem cell transplant for blood cancer. Researchers will follow 100 adult patients to see if these markers can give an early warning. The…
Matched conditions: GVHD,ACUTE
Sponsor: Henry Ford Health System • Aim: Knowledge-focused
Last updated May 20, 2026 11:57 UTC